ClinicalTrials.gg
Status unknownNCT03621527VTB EPI-ALUpdated Aug 8, 2018

Efficacy of Fluoroscopy-guided Epidural Anesthesia for Osteoporotic Vertebral Compression Fracture Treated by Percutaneous Vertebroplasty

An interventional study of anesthesia combined with intravenous analgesia by remifentanil and fluoroscopy-guided epidural anesthesia in Vertebral Compression Fractures in Osteoporotic Patients, sponsored by University Hospital, Strasbourg, France. Status unknown at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-08.

Sponsored by University Hospital, Strasbourg, France · Not applicable, Interventional, and Other

The sponsor has not verified this record recently (last verified Jun 2018), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Vertebral compression fractures in osteoporotic patients is a major healthcare problem. Percutaneous vertebroplasty is commonly used to restore stability of the vertebra and to alleviate pain. However, the anesthetic techniques commonly used during these procedures such general anesthesia or a combination of local anesthesia and sedation are not satisfying as they are associated either with side effects or insufficient pain reduction.

This study compares the standard procedure of local anesthesia to a new technique of fluoroscopy-guided epidural anesthesia carried out by the radiologist.

The investigator's hypothesis is that fluoroscopy-guided epidural anesthesia

  • provides better pain relief during the injection of high viscosity cement
  • and thus, reduces the need of additional intravenous analgesia by remifentanil (morphine analogue)
  • minimizes remifentanil potential adverse effects such as respiratory depression, hypoxemia, pruritus and nausea
  • improves working conditions and satisfaction of the radiologist
  • improves the global satisfaction of the patient

It is a monocentric, prospective, comparative and randomized study.

02

Conditions studied

  • Vertebral Compression Fractures in Osteoporotic Patients

Browse trials for

03

In context

Fractures, Compression

50 studies on the registry are indexed under Fractures, Compression; 10 are open to participants now.

This study's planned enrollment of 100 is above the median of 73 across 32 interventional studies indexed under Fractures, Compression.

Browse Fractures, Compression studies →

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 999 studies on the registry; 358 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Two osteoporotic vertebra compression fractures in the low thoracic or lumbar spine
  • men and women > 18 years old
  • patients with healthcare insurance
  • signed and dated

Exclusion criteria

Exclusion Criteria:

  • men and women \< 18 years
  • pregnant or breastfeeding women
  • patients under trusteeship or guardianship or patients under the protection of court
  • bad comprehension or cooperation
  • bleeding disorders
  • local or general infection
  • intracerebral or severe cardiac affections
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Standard group

    For each vertebra treated: 10 ml of lidocaine hydrochloride 1% are applied to the skin and the lower structures including the periosteum. An additional, anesthesia combined with intravenous analgesia by remifentanil is provided and adapted to the patients needs during the whole procedure

    Other: anesthesia combined with intravenous analgesia by remifentanil

  • Experimental
    Epidural group

    Fluoroscopy-guided epidural anesthesiaI is the identification of the epidural space using fluoroscopy and the injection of a small quantity of contrast medium or air. According to patient's height, 10-15 ml of lidocaine hydrochloride 1% are injected by the radiologist into the epidural space. An additional, anesthesia combined with intravenous analgesia by remifentanil is provided and adapted to the patients needs during the whole procedure

    Other: fluoroscopy-guided epidural anesthesia

Interventions

  • Otheranesthesia combined with intravenous analgesia by remifentanil

    intravenous analgesia by remifentanil is provided and adapted to the patients' needs during the whole procedure

  • Otherfluoroscopy-guided epidural anesthesia

    Identification of the epidural space using fluoroscopy and the injection of a small quantity of contrast medium or air. An additional, anesthesia combined with intravenous analgesia by remifentanil is provided and adapted to the patients needs during the whole procedure

06

What researchers measure

Primary outcomes

  1. Morphine used in the procedure

    Maximal target dose of remifentanil used during the procedure to obtain a satisfactory pain reduction during cement injection

    Time frame: 1 day

07

Study locations

1 of 1 sites recruiting
  • Hôpitaux Universitaires de Strasbourg
    Strasbourg, 67000, France
    Recruiting
    • Thi Mai BERNEMANN, PH · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2018 (actual). Primary completion is estimated for May 2019, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2018
First posted
Aug 8, 2018
StartActual
May 3, 2018
Primary completionEst.
May 2019
CompletionEst.
May 2019
Last update
Aug 8, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03621527
Responsible party
Sponsor
First posted
Aug 8, 2018
Start date
May 3, 2018
Primary completion
May 2019 (estimated)
Completion
May 2019 (estimated)
Last update
Aug 8, 2018

Study contacts

Thi Mai BERNEMANN, PI
Contact
thimai.bernemann@chru-strasbourg.fr
03 69 55 16 23 ext. +33
Thi Mai BERNEMANN
principal investigator · Hôpitaux Universitaires de Strasbourg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion